All these biological data support the therapeutic potential of this thieno[3,2-d]pyrimidine for the treatment of highly invasive cancers, including drug-resistant AML harboring recalcitrant FLT3 and/or FAK mutants [55]. This evidence concerns the gene PTK2 and cancer.